IVIG - BMC HealthNet Plan

130. Seider N, Beiran I, Scharf J, et al. Intravenous immunoglobulin therapy for
resistant ocular Behcet’s disease. Br J Ophthalmol. 2001;85:1287-1288.
131. Vats A, Randhawa PS, Shapiro R. Diagnosis and treatment of BK virusassociated
transplant nephropathy. Adv Exp Med Biol. 2006;577:213-227.
132. Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a
treatment for BK virus associated nephropathy: one-year follow-up of renal allograft
recipients. Transplantation. 2006;81:117-120.
133. Chrissafidou A, Malek M, Musch E. Experimental Study on the Use of
Intravenous Immunoglobulin (IVIg) in Patients with Steroid-Resistant Crohn's
Disease. Z Gastroenterol. 2007;45:605-608.
134. Colagiuri S, Leong GM, Thayer Z, et al. Intravenous immunoglobulin therapy for
autoimmune diabetes mellitus. Clin Exp Rheumatol. 1996;14 Suppl 15:S93-97.
135. Heinze E. Immunoglobulins in children with autoimmune diabetes mellitus. Clin
Exp Rheumatol. 1996;14 Suppl 15:S99-102.
136. Aukrust P, Yndestad A, Ueland T, et al. The role of intravenous immunoglobulin
in the treatment of chronic heart failure. Int. J. Cardiol. 2006;112:40-45.
137. Cordonnier C, Chevret S, Legrand M, et al; GREFIG Study Group. Should
immunoglobulin therapy be used in allogeneic stem-cell transplantation A
randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann
Intern Med. 2003;139:8-18.
138. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in
haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003;88:F6-
10.
139. Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple
sclerosis. Cochrane Database Syst Rev. 2003;(4):CD002936.
140. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in
secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet.
2004;364:1149-1156.
141. Goodin DS, Frohman EM, Garmany GP Jr, et al; Therapeutics and Technology
Assessment Subcommittee of the American Academy of Neurology and the MS
Council for Clinical Practice Guidelines. Disease modifying therapies in multiple
sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of
the American Academy of Neurology and the MS Council for Clinical Practice
Guidelines. Neurology. 2002;58:169-178.
142. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in
preterm and/or low-birth-weight infants. Cochrane Database Syst Rev.
2004;(1):CD000361.
143. Fanaroff AA, Korones SB, Wright LL, et al. A controlled trial of intravenous
immune globulin to reduce nosocomial infections in very-low-birth-weight infants.
National Institute of Child Health and Human Development Neonatal Research
Network. N Engl J Med. 1994;330:1107-1113.
144. Kurlan R, Kaplan EL. The pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infection (PANDAS) etiology for tics and obsessive-
This guideline provides information on BMC HealthNet Plan claims adjudication processing guidelines. The use of this
guideline is not a guarantee of payment and will not determine how a specific claim(s) will be paid. Reimbursement is
based on member benefits and eligibility, medical necessity review, where applicable, coordination of benefits, adherence
to Plan policies, clinical coding criteria, and the BMC HealthNet Plan agreement with the rendering or dispensing provider.
Reimbursement policies may be amended at BMC HealthNet Plan’s discretion. BMC HealthNet Plan will always use the
most recent CPT and HCPCS coding guidelines.
BMC HealthNet Plan – IVIG
42 of 45